Abstract:
:Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor. Conventional treatment options include surgery and radiotherapy but there is no validated medical option. Recent evidence suggests that Merlin deficiency may result in abnormal activation of receptor tyrosine kinases (RTKs) and downstream signaling, promoting tumor growth. Although small-molecule RTK inhibitors are widely available for clinical use, no such therapy has been validated in patients with VS. To screen for RTK activation, surgical VS specimens from patients with and without NF2 were analyzed by phospho-RTK profiling arrays. Downstream signaling pathway activation was analyzed by phospho-MAPK arrays. Activated RTKs and downstream kinases were validated immunohistochemically in corresponding formalin-fixed, paraffin-embedded tissues. Phospho-RTK arrays and immunohistochemistry showed consistent overexpression and activation of EGFR family receptors and evidence of ERK1/2 downstream signaling was observed in all samples analyzed (n = 11). Based on the findings, the small-molecule EGFR/ErbB2 kinase inhibitor lapatinib was selected for evaluation of target inhibition and treatment efficacy in our in vitro human schwannoma model. EGFR/ErbB2 targeted therapy with lapatinib inhibited ErbB2 phosphorylation and survivin upregulation, as well as downstream ERK1/2 and AKT activation, resulting in decreased proliferation. We conclude that EGFR family receptor activation is a consistent feature of both sporadic and NF2-related VS. Molecular targeted therapy with lapatinib downregulates survivin and has antiproliferative activity in a preclinical VS model. Based on these findings, a clinical trial with lapatinib for the treatment of VS is currently underway.
journal_name
Neuro Oncoljournal_title
Neuro-oncologyauthors
Ammoun S,Cunliffe CH,Allen JC,Chiriboga L,Giancotti FG,Zagzag D,Hanemann CO,Karajannis MAdoi
10.1093/neuonc/noq012subject
Has Abstractpub_date
2010-08-01 00:00:00pages
834-43issue
8eissn
1522-8517issn
1523-5866pii
noq012journal_volume
12pub_type
杂志文章相关文献
NEURO-ONCOLOGY文献大全abstract:Background:Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly diagnosed and posttreatment settings. Methods...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章
doi:10.1093/neuonc/noy022
更新日期:2018-08-02 00:00:00
abstract:BACKGROUND:Malignant glioma is an aggressive cancer requiring new therapeutic targets. MicroRNAs (miRNAs) regulate gene expression post transcriptionally and are implicated in cancer development and progression. Deregulated expressions of several miRNAs, specifically hsa-miR-184, correlate with glioma development. MET...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou220
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:Cisplatin-Induced Peripheral Neuropathy (CIPN) is a frequent serious dose-dependent adverse event that can determine dosage limitations for cancer treatment. CIPN severity correlates with the amount of platinum detected in sensory neurons of the dorsal root ganglia (DRG). However, the exact pathophysiology o...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa151
更新日期:2020-06-29 00:00:00
abstract::The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast mate...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nox175
更新日期:2018-01-22 00:00:00
abstract::Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nou222
更新日期:2014-10-01 00:00:00
abstract:BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...
journal_title:Neuro-oncology
pub_type: 杂志文章,随机对照试验
doi:10.1093/neuonc/now007
更新日期:2016-06-01 00:00:00
abstract:BACKGROUND:To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation. METHODS:A retrospective analysis was performed on 291 patients with GBM. The efficacies of VPA and LE...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not057
更新日期:2013-07-01 00:00:00
abstract:BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...
journal_title:Neuro-oncology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1093/neuonc/not049
更新日期:2013-07-01 00:00:00
abstract:BACKGROUND:The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but t...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov307
更新日期:2016-02-01 00:00:00
abstract::The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy. Median overall survival increased from 7...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nou297
更新日期:2014-12-01 00:00:00
abstract:BACKGROUND:We assessed the longitudinal hazard characteristics for death and progression in patients with glioblastoma, evaluated the impact of prognostic factors and treatment on the hazard within different time intervals to determine if effects are time varying, and quantified the influence of progression on survival...
journal_title:Neuro-oncology
pub_type: 杂志文章,随机对照试验
doi:10.1093/neuonc/nov009
更新日期:2015-07-01 00:00:00
abstract:BACKGROUND:Hippocampal avoidance has been suggested as a strategy to reduce short-term memory decline in adults receiving whole-brain radiation therapy (RT). The purpose of this study was to determine whether the hippocampal dose in children and adolescents undergoing RT for low-grade glioma was associated with memory,...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz068
更新日期:2019-09-06 00:00:00
abstract:BACKGROUND:The transcription factor homeobox C9 (HOXC9) plays a crucial role in developmental regulatory systems, where it determines the specific positional identities of cells along the anteroposterior axis. The expression of HOXC9 has been found to be dysregulated in some cancers such as lung cancer, breast cancer, ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov281
更新日期:2016-06-01 00:00:00
abstract:BACKGROUND:Young age is a favorable prognostic factor for patients with glioblastoma multiforme (GBM). We reviewed the outcomes and molecular tumor characteristics of adolescent and young adult patients with GBM treated in 2 Austrian centers. PATIENTS AND METHODS:Data on patients with histologically proven primary GBM...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos283
更新日期:2013-01-01 00:00:00
abstract::Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither prophylaxis nor specific treatment is available, and only symptomatic treatment can be offered. Neurotoxic drugs are becom...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nos203
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND:Temozolomide (TMZ) resistance in Glioblastoma (GBM) is mediated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). MGMT promoter methylation (occurs in about 40% patients) is associated with loss of MGMT expression (MGMT-) that compromises DNA repair, leading to a favorable response to ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noab003
更新日期:2021-01-12 00:00:00
abstract::The subventricular zone (SVZ) lines the lateral ventricles and represents the origin of neural and some cancer stem cells. Tumors contacting the SVZ may be more invasive with higher potential to recruit migratory progenitor cells. Our specific aim was to determine whether SVZ involvement in glioblastoma multiforme (GB...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nos268
更新日期:2013-01-01 00:00:00
abstract:Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nox091
更新日期:2017-10-19 00:00:00
abstract:Background:Malignant glioma (MG) is a devastating neuro-oncologic disease with almost invariably poor prognosis. Prognostic awareness (PA) is the awareness of incurable disease and shortened life expectancy (LE). Accurate PA is associated with favorable psychological outcomes at the end of life (EoL) for patients with ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nox117
更新日期:2017-10-19 00:00:00
abstract::Although treatment of medulloblastoma has improved, at least 30% of patients with this tumor die of progressive disease. Unfortunately, many of the children who survive suffer long-term treatment-related morbidity. Previous studies have demonstrated the efficacy of using oncolytic viruses to eradicate brain tumors. Th...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq057
更新日期:2010-10-01 00:00:00
abstract:BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noz215
更新日期:2020-04-15 00:00:00
abstract::To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1215/15228517-2008-103
更新日期:2009-06-01 00:00:00
abstract::The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either...
journal_title:Neuro-oncology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1093/neuonc/2.4.213
更新日期:2000-10-01 00:00:00
abstract::Microglia, which contribute substantially to the tumor mass of glioblastoma, have been shown to play an important role in glioma growth and invasion. While a large number of experimental studies on functional attributes of microglia in glioma provide evidence for their tumor-supporting roles, there also exist hints in...
journal_title:Neuro-oncology
pub_type: 杂志文章,评审
doi:10.1093/neuonc/nos116
更新日期:2012-08-01 00:00:00
abstract:BACKGROUND:The influence of survivin isoforms on outcome in glioblastoma is poorly understood. We analyzed the dominant anti-apoptotic transcript variants of survivin using expression data and modeled them in vivo to determine their impact on glioma formation and progression. METHODS:Using data from low- and high-grad...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nou034
更新日期:2014-09-01 00:00:00
abstract:Background:Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate-limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in gliobla...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noy012
更新日期:2018-07-05 00:00:00
abstract:BACKGROUND:Altered expression of micro(mi)RNAs has been shown to be associated with tumorigenesis and tumor progression. The expression of phosphatase and tensin homolog (PTEN) plays an important role in glioma and is regarded as a prognostic marker of glioma patients. The goal of this study was to investigate the func...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/not107
更新日期:2013-11-01 00:00:00
abstract:BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly fo...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/nov181
更新日期:2015-12-01 00:00:00
abstract::We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of this study was to ...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noq003
更新日期:2010-08-01 00:00:00
abstract:BACKGROUND:EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or Temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of radiotherapy on memory functioning, this stu...
journal_title:Neuro-oncology
pub_type: 杂志文章
doi:10.1093/neuonc/noaa252
更新日期:2020-11-01 00:00:00